Literature DB >> 15205195

5-Fluorouracil incorporation into RNA and DNA in relation to thymidylate synthase inhibition of human colorectal cancers.

P Noordhuis1, U Holwerda, C L Van der Wilt, C J Van Groeningen, K Smid, S Meijer, H M Pinedo, G J Peters.   

Abstract

BACKGROUND: The mechanism of action of 5-fluorouracil (5-FU) has been associated with inhibition of thymidylate synthase (TS) and incorporation of 5-FU into RNA and DNA, but limited data are available in human tumor tissue for the latter. We therefore measured incorporation in human tumor biopsy specimens after administration of a test dose of 5-FU alone or with leucovorin. PATIENTS AND METHODS: Patients received 5-FU (500 mg/m(2)) with or without high-dose leucovorin, low-dose leucovorin or l-leucovorin, and biopsy specimens were taken after approximately 2, 24 or 48 h. Tissues were pulverized and extracted for nucleic acids. 5-FU incorporation was measured using gas chromatography/mass spectrometry after complete degradation to bases of isolated RNA and DNA.
RESULTS: Maximal incorporation into RNA (1.0 pmol/micrograms RNA) and DNA (127 fmol/micrograms DNA) of 59 and 46 biopsy specimens, respectively, was found at 24 h after 5-FU administration. Incorporation into RNA but not DNA was significantly correlated with intratumoral 5-FU levels. However, DNA incorporation was significantly correlated with the RNA incorporation. Primary tumor tissue, liver metastasis and normal mucosa did not show significant differences, while leucovorin had no effect. Neither for RNA (30 patients) nor DNA (24 patients) incorporation was a significant correlation with response to 5-FU therapy found. However, in the same group of patients, response was significantly correlated to TS inhibition (mean TS in responding and non-responding groups 45 and 231 pmol/h/mg protein, respectively; P=0.001).
CONCLUSIONS: 5-FU is incorporated at detectable levels into RNA and DNA of human tumor tissue, but no relation between the efficacy of 5-FU treatment and incorporation was found, in contrast to TS.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15205195     DOI: 10.1093/annonc/mdh264

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  64 in total

1.  Improved Antitumor Activity of the Fluoropyrimidine Polymer CF10 in Preclinical Colorectal Cancer Models through Distinct Mechanistic and Pharmacologic Properties.

Authors:  William H Gmeiner; Anthony Dominijanni; Alex O Haber; Lais P Ghiraldeli; David L Caudell; Ralph D'Agostino; Boris C Pasche; Thomas L Smith; Zhiyong Deng; Sezgin Kiren; Chinnadurai Mani; Komaraiah Palle; Jonathan R Brody
Journal:  Mol Cancer Ther       Date:  2020-12-23       Impact factor: 6.261

2.  Reexamining a proposal: thymidylate synthase 5'-untranslated region as a regulator of translation efficiency.

Authors:  Soma Ghosh; Jordan M Winter; Kalpesh Patel; Scott E Kern
Journal:  Cancer Biol Ther       Date:  2011-10-15       Impact factor: 4.742

Review 3.  The applications of the novel polymeric fluoropyrimidine F10 in cancer treatment: current evidence.

Authors:  William H Gmeiner; Waldemar Debinski; Carol Milligan; David Caudell; Timothy S Pardee
Journal:  Future Oncol       Date:  2016-06-09       Impact factor: 3.404

4.  Chemoresistance to 5-FU inhibited by 635 nm LED irradiation in CD133+ KB cell line.

Authors:  Donghwi Kim; Mineon Park; Hyunwoong Jang; Hoon Hyun; Wonbong Lim
Journal:  Lasers Med Sci       Date:  2017-09-27       Impact factor: 3.161

5.  Protonation preferentially stabilizes minor tautomers of the halouracils: IRMPD action spectroscopy and theoretical studies.

Authors:  K T Crampton; A I Rathur; Y-w Nei; G Berden; J Oomens; M T Rodgers
Journal:  J Am Soc Mass Spectrom       Date:  2012-07-21       Impact factor: 3.109

6.  Tumor-infiltrating γδT cells predict prognosis and adjuvant chemotherapeutic benefit in patients with gastric cancer.

Authors:  Jieti Wang; Chao Lin; He Li; Ruochen Li; Yifan Wu; Hao Liu; Heng Zhang; Hongyong He; Weijuan Zhang; Jiejie Xu
Journal:  Oncoimmunology       Date:  2017-07-24       Impact factor: 8.110

7.  Piper betle leaf extract enhances the cytotoxicity effect of 5-fluorouracil in inhibiting the growth of HT29 and HCT116 colon cancer cells.

Authors:  Pek Leng Ng; Nor Fadilah Rajab; Sue Mian Then; Yasmin Anum Mohd Yusof; Wan Zurinah Wan Ngah; Kar Yong Pin; Mee Lee Looi
Journal:  J Zhejiang Univ Sci B       Date:  2014-08       Impact factor: 3.066

Review 8.  Targeted nanoparticles for colorectal cancer.

Authors:  Bruno A Cisterna; Nazila Kamaly; Won Il Choi; Ali Tavakkoli; Omid C Farokhzad; Cristian Vilos
Journal:  Nanomedicine (Lond)       Date:  2016-08-16       Impact factor: 5.307

Review 9.  Esophageal cancer: The latest on chemoprevention and state of the art therapies.

Authors:  Gregoire F Le Bras; Muhammad H Farooq; Gary W Falk; Claudia D Andl
Journal:  Pharmacol Res       Date:  2016-08-24       Impact factor: 7.658

10.  Promoter methylation and large intragenic rearrangements of DPYD are not implicated in severe toxicity to 5-fluorouracil-based chemotherapy in gastrointestinal cancer patients.

Authors:  Joana Savva-Bordalo; João Ramalho-Carvalho; Manuela Pinheiro; Vera L Costa; Angelo Rodrigues; Paula C Dias; Isabel Veiga; Manuela Machado; Manuel R Teixeira; Rui Henrique; Carmen Jerónimo
Journal:  BMC Cancer       Date:  2010-09-01       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.